Search research articles
Contact Us
Filters
Showing results (71-80 of 83) with videos related to
Page
of 9
Sort By:
Indian Heart Journal
|
March 29, 2025
Comparative evaluation of machine learning models versus TIMI score in ST-segment-elevation myocardial infarction patients
Mohit D Gupta, Dixit Goyal, Shekhar Kunal, et al.
The Lancet. Rheumatology
|
January 27, 2024
Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study
Christopher D Buckley, Jesus A Simón-Campos, Vyacheslav Zhdan, et al.
International Journal of Cardiology
|
May 16, 2022
Machine learning based model for risk prediction after ST-Elevation myocardial infarction: Insights from the North India ST elevation myocardial infarction (NORIN-STEMI) registry
Manu Kumar Shetty, Shekhar Kunal, M P Girish, et al.
The Lancet. Rheumatology
|
January 26, 2024
Anti-granulocyte-macrophage colony-stimulating factor antibody otilimab in patients with hand osteoarthritis: a phase 2a randomised trial
Georg Schett, Chris Bainbridge, Mario Berkowitz, et al.
The Lancet. Rheumatology
|
January 27, 2024
MRI of the joint and evaluation of the granulocyte-macrophage colony-stimulating factor-CCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic study
Mark C Genovese, Mario Berkowitz, Philip G Conaghan, et al.
BMJ Open
|
March 5, 2025
Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X)
Michael E Weinblatt, Peter C Taylor, Iain B McInnes, et al.
Annals of the Rheumatic Diseases
|
September 11, 2023
Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)
Peter C Taylor, Michael E Weinblatt, Iain B McInnes, et al.
Indian Heart Journal
|
March 14, 2021
Design and rationale of an intelligent algorithm to detect BuRnoUt in HeaLthcare workers in COVID era using ECG and artificiaL intelligence: The BRUCEE-LI study
Mohit D Gupta, Ankit Bansal, Prattay G Sarkar, et al.
Annals of the Rheumatic Diseases
|
September 12, 2023
Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)
Roy M Fleischmann, Désirée van der Heijde, Vibeke Strand, et al.
Medical Image Analysis
|
November 20, 2022
SegPC-2021: A challenge & dataset on segmentation of Multiple Myeloma plasma cells from microscopic images
Anubha Gupta, Shiv Gehlot, Shubham Goswami, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 83) with videos related to
Sort By:
Page
of 9
Indian Heart Journal
|
March 29, 2025
Comparative evaluation of machine learning models versus TIMI score in ST-segment-elevation myocardial infarction patients
Mohit D Gupta, Dixit Goyal, Shekhar Kunal, et al.
The Lancet. Rheumatology
|
January 27, 2024
Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study
Christopher D Buckley, Jesus A Simón-Campos, Vyacheslav Zhdan, et al.
International Journal of Cardiology
|
May 16, 2022
Machine learning based model for risk prediction after ST-Elevation myocardial infarction: Insights from the North India ST elevation myocardial infarction (NORIN-STEMI) registry
Manu Kumar Shetty, Shekhar Kunal, M P Girish, et al.
The Lancet. Rheumatology
|
January 26, 2024
Anti-granulocyte-macrophage colony-stimulating factor antibody otilimab in patients with hand osteoarthritis: a phase 2a randomised trial
Georg Schett, Chris Bainbridge, Mario Berkowitz, et al.
The Lancet. Rheumatology
|
January 27, 2024
MRI of the joint and evaluation of the granulocyte-macrophage colony-stimulating factor-CCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic study
Mark C Genovese, Mario Berkowitz, Philip G Conaghan, et al.
BMJ Open
|
March 5, 2025
Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X)
Michael E Weinblatt, Peter C Taylor, Iain B McInnes, et al.
Annals of the Rheumatic Diseases
|
September 11, 2023
Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)
Peter C Taylor, Michael E Weinblatt, Iain B McInnes, et al.
Indian Heart Journal
|
March 14, 2021
Design and rationale of an intelligent algorithm to detect BuRnoUt in HeaLthcare workers in COVID era using ECG and artificiaL intelligence: The BRUCEE-LI study
Mohit D Gupta, Ankit Bansal, Prattay G Sarkar, et al.
Annals of the Rheumatic Diseases
|
September 12, 2023
Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)
Roy M Fleischmann, Désirée van der Heijde, Vibeke Strand, et al.
Medical Image Analysis
|
November 20, 2022
SegPC-2021: A challenge & dataset on segmentation of Multiple Myeloma plasma cells from microscopic images
Anubha Gupta, Shiv Gehlot, Shubham Goswami, et al.
Page
of 9